Literature DB >> 9454655

Taxol hypersensitivity: rapid retreatment is safe and cost effective.

J K Olson1, A K Sood, J I Sorosky, B Anderson, R E Buller.   

Abstract

OBJECTIVE: The aim of this study was to describe a rapid retreatment strategy that is safe and cost effective in ovarian cancer patients with Taxol hypersensitivity reactions.
METHODS: A retrospective review of 91 women receiving Taxol-based chemotherapy at the University of Iowa Hospitals and Clinics between October 1991 and July 1996 was performed. All patients who developed hypersensitivity reactions to Taxol were identified and their treatment course and outcome were reviewed.
RESULTS: Seven women (7.7%) developed hypersensitivity reactions. All received standard premedications consisting of corticosteroids and histamine blockers. Six of the seven were rechallenged with the original Taxol solution starting at a slower rate. In these cases the infusion was completed within 24 h and none of these patients had a reaction in subsequent courses. One patient was not retreated due to the severity of her reaction during a 3-h infusion.
CONCLUSION: Retreatment with the original Taxol solution is safe and cost effective in most patients with hypersensitivity reactions. Retreatment with Taxol should be completed within 24 h. A schema for retreatment is presented. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9454655     DOI: 10.1006/gyno.1997.4906

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

Review 1.  Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.

Authors:  G L Plosker; M Hurst
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.

Authors:  Matthieu Picard; Mariana C Castells
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

3.  Oral premedication for the prevention of hypersensitivity reactions to paclitaxel.

Authors:  Jamal Zidan; O Hussein; A Abzah; S Tamam; Z Farraj; E Friedman
Journal:  Med Oncol       Date:  2008-03-25       Impact factor: 3.064

4.  A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature.

Authors:  Patricia A Demoor; Yuri Matusov; Colleen Kelly; Shobha Kolan; Linda Barnachea; Lyudmila A Bazhenova
Journal:  J Cancer       Date:  2011-03-10       Impact factor: 4.207

5.  Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.

Authors:  Romualdo Barroso-Sousa; Ines Vaz-Luis; Antonio Di Meglio; Jiani Hu; Tianyu Li; Rebecca Rees; Natalie Sinclair; Lindsey Milisits; Jose Pablo Leone; Michael Constantine; Meredith Faggen; Frederick Briccetti; Caroline Block; Ann Partridge; Harold Burstein; Adrienne G Waks; Nabihah Tayob; Lorenzo Trippa; Sara M Tolaney; Michael J Hassett; Eric P Winer; Nancy U Lin
Journal:  Oncologist       Date:  2021-09-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.